Quantitative Grading of Fuchs Endothelial Corneal Dystrophy Powered by AI
GuttEye
Fuchs Endothelial Corneal Dystrophy (FECD) is one of the leading causes of corneal transplantation worldwide. Yet disease progression is still commonly assessed using subjective grading systems that lack the sensitivity required for modern clinical research and long-term patient monitoring. Developed in collaboration with the team of Dr. Mark Greiner at the University of Iowa, GuttEye automatically detects, segments, and quantifies guttae from specular microscopy images, providing clinicians and researchers with objective and reproducible measurements of disease severity.
By transforming specular microscopy images into quantitative clinical data, GuttEye enables more accurate disease assessment, standardized follow-up, and improved evaluation of therapeutic efficacy. Turn subjective grading into measurable clinical evidence.
Monitor Disease Progression with Confidence
Traditional FECD grading methods often lack the precision needed to detect subtle changes over time, making patient follow-up and clinical trial evaluation particularly challenging.
GuttEye introduces an objective quantitative approach through its proprietary GAR% score, enabling more sensitive monitoring of disease progression and treatment response.
Our solution helps organizations:
- Standardize FECD grading
- Generate reproducible quantitative endpoints
- Reduce inter- and intra-observer variability
- Monitor disease progression over time
- Support clinical decision-making
- Improve patient follow-up
- Accelerate ophthalmology research
- Facilitate clinical trial assessments
By providing objective measurements instead of subjective observations, GuttEye helps clinicians and researchers make more confident decisions.
Designed for Clinical Practice and Research
GuttEye combines advanced image analysis and artificial intelligence to deliver rapid, reliable, and clinically meaningful results.
Key Capabilities :
- Automated guttae segmentation
- Quantitative GAR% disease score
- Automated image analysis in seconds
- Longitudinal patient monitoring
- Automatic image registration and alignment
- Comparison of identical corneal regions over time
- Manual review and correction tools
- Reproducible measurements across visits and operators
The result is a robust and scalable workflow that supports both routine clinical practice and large-scale research projects.
Who Benefits from GuttEye ?
From Corneal Images
to Clinical Endpoints
As new therapies for Fuchs dystrophy continue to emerge, researchers and sponsors require more sensitive biomarkers capable of measuring treatment efficacy within clinically relevant timeframes. GuttEye was designed to address this need. By combining AI-powered segmentation, quantitative scoring, and longitudinal image tracking, GuttEye provides a robust framework for both patient management and clinical research.
From image acquisition to disease monitoring, GuttEye transforms specular microscopy into a powerful tool for quantitative FECD assessment.
- Automated AI-powered guttae segmentation
- Objective and reproducible FECD grading
- Quantitative GAR% endpoint
- Longitudinal disease tracking
- Designed for clinical research and clinical practice
- Developed with international FECD experts
- Ideal for emerging therapeutic studies in Fuchs dystrophy
- Fuchs Dystrophy Screening
- FECD Severity Assessment
- Longitudinal Patient Monitoring
- Corneal Endothelium Evaluation
- Clinical Trial Imaging Endpoints
- Treatment Response Monitoring
- Pharmaceutical Research Programs
- AI-Assisted Corneal Imaging Analysis
Looking for a Reliable Imaging Endpoint
for FECD Clinical Trials ?
Discover how GuttEye helps researchers generate objective
and sensitive measurements of disease progression.